According to DelveInsight's' estimates, the adrenocortical carcinoma market in 7MM is expected to show positive growth, during the forecast period (2024-2034), mainly attributed to the anticipated
Bellevue Group AG trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 5.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,430,500 shares of the company’s stock after selling 153,050 shares during the period. Neurocrine […]
Sectoral Asset Management Inc. lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 10.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,445 shares of the company’s stock after buying an additional 410 shares during the period. Sectoral Asset Management […]
Rhenman & Partners Asset Management AB grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 13.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 62,000 shares of the company’s stock after acquiring an additional 7,434 shares during the period. Rhenman […]
BOSTON — Adults with congenital adrenal hyperplasia receiving an oral nonsteroidal treatment saw a marked reduction in daily glucocorticoid dose at 24 weeks with maintenance of androgen control compared with placebo, researchers reported.
The data suggest that the treatment, crinecerfont (Neurocrine Biosciences), a selective corticotropin-releasing factor type 1 receptor, could offer an